As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them.

Older adults living with Type 2 diabetes face more than just blood sugar concerns. New research shows some of the most ...

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become household names in recent years, hailed as revolutionary treatments for type 2 diabetes and obesity.